News

RPJ’s Jill Kahn Marshall, Daniel J. Ain, and Hannah R. Brefeld Named to the 2026 Lawdragon 500 X – The Next Generation

RPJ is delighted to share that once again, our colleagues Jill Kahn Marshall, Daniel Ain, and Hannah Brefeld have all been named to this year’s Lawdragon 500 X – The Next Generation list. Published annually, the Lawdragon 500 X honors the rising generation of legal leaders whose exceptional talent, innovative thinking, and...

Read More

RPJ is a Proud Sponsor of DC/DOX 2026

Supporting organizations that champion powerful storytelling is deeply important to RPJ, which is why we are proud to sponsor DC/DOX 2026, taking place June 11-14. DC/DOX continues to create a vital space for dialogue, discovery, and engagement through films that highlight complex issues, challenge perspectives, and inspire meaningful conversations. We...

Read More

RPJ’s Gregory P. Feit Quoted in Law360 on Patagonia-Pattie Gonia Trademark Dispute

RPJ’s Gregory P. Feit was recently featured in a Law360 article examining the intersection of trademark enforcement, parody, commercial speech, and brand protection in the closely watched dispute between outdoor apparel company Patagonia and environmental activist and drag performer “Pattie Gonia.” The case centers on a trademark infringement lawsuit filed...

Read More

Preserving Jurisdiction Over Arbitration: The Supreme Court’s Decision in Jules v. Andre Balazs Properties

by Alice K. Jump and Lucia Mead On May 14, 2026, the Supreme Court issued a unanimous decision further clarifying the scope of federal jurisdiction under the Federal Arbitration Act (“FAA”). In an opinion authored by Justice Sotomayor, the Supreme Court in Jules v. Andre Balazs Properties clarified that federal...

Read More

Hikma v. Amarin: Supreme Court Examines Induced Infringement in the Context of Generic Drug Labeling

by Nafsika Karavida and Lucia Mead Last month, the Supreme Court of the United States heard oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a landmark pharmaceutical patent dispute concerning whether a generic drug manufacturer may face liability for induced patent infringement after marketing a “skinny-label” generic...

Read More